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Abstract: Three-dimensional structural information is critical for understanding functional 
protein properties and the precise mechanisms of protein functions implicated in physiological 
and pathological processes. Comparison and detection of protein binding sites are key steps for 
annotating structures with functional predictions and are extremely valuable steps in a drug design 
process. In this research area, MED-SuMo is a powerful technology to detect and characterize 
similar local regions on protein surfaces. Each amino acid residue’s potential chemical interac-
tions are represented by speciﬁ  c surface chemical features (SCFs). The MED-SuMo heuristic is 
based on the representation of binding sites by a graph structure suitable for exploration by an 
efﬁ  cient comparison algorithm. We use this approach to analyze one particular SCOP super-
family which includes HSP90 chaperone, MutL/DNA topoisomerase, histidine kinases, and 
α-ketoacid dehydrogenase kinase C (BCK). They share a common fold and a common region 
for ATP-binding. To analyze both similar and differing features of this fold, we use a novel 
classiﬁ  cation method, the MED-SuMo multi approach (MED-SMA). We highlight common and 
distinct features of these proteins. The different clusters created by MED-SMA yield interesting 
observations. For instance, one cluster gathers three types of proteins (HSP90, topoisomerase 
VI, and BCK) which all bind the drug radicicol.
Keywords: functional classiﬁ  cation, surface similarity, protein surface chemical feature, 
radicicol binding
Introduction
Protein three-dimensional (3D) structural information help to understand functional 
protein properties and the precise mechanisms of proteins implicated in physiological 
and pathological processes.1 Knowledge of 3D protein structures linked to small 
molecules can be used for structure- and ligand-based drug design approaches.2,3 
It also gives direct hints to the protein functional mechanisms. A protein’s activity 
often depends on a small, highly conserved set of residues within the binding site.4,5 
Comparison and detection of protein binding sites are key steps for annotating struc-
tures with functional predictions. In this ﬁ  eld, Structural Genomics consortia have 
radically changed mankind’s base of protein structural knowledge. Their endeavors 
have permitted the resolution of numerous structures characterized as “Unknown 
function”, and multiple functional sites are not associated with any known binding 
partner.6 Consequently, the development of computational methods to functionally 
annotate protein structures has become a major research area.
The simplest approaches are based on sequence analogy, eg, PSI-BLAST,7 or on 
the characterization of functional patterns or proﬁ  les, eg, PROSITE.8 They help to draw 
on knowledge and assumptions of protein functions in assigning predicted functions. 
However, they cannot embrace the complexity of local 3D folds. During the past 
years, various methods to compare and detect binding sites have been elaborated; they 
use diverse types of descriptors. Their general purpose is often to create automated 
functional annotation methods independent from amino acid sequence or from Drug Design, Development and Therapy 2009:3 60
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global fold similarity, eg, CavBase,9 SiteEngine,10 FLAP,11 
CPASS,12 or eF-seek.13
Some of these approaches share gross features but they 
also have notable distinctions. For instance, SiteEngine 
and CavBase both associate physico-chemical properties to 
structural characteristics. However, SiteEngine allows the 
comparison of entire protein surfaces to a binding site data-
base, whereas CavBase is restricted to cavity comparisons. 
The web-based version of SiteEngine is restricted to the 
comparison of a single site versus one protein structure.10 
CavBase detects related cavities based on a clique detection 
algorithm9 while CPASS comparison uses an alignment of 
binding site pairs through a root–mean–square–difference 
(RMSD) scoring function.12 Roterman has developed an 
innovative methodology based on irregular hydrophobicity 
distribution.14 A few other methods are based on the detec-
tion of conserved residues to characterize binding sites, eg, 
evolutionary trace method15–17 or sequence alignment with a 
dedicated dataset as Catalytic Site Atlas (CSA).4
In this research area, SuMo is a powerful technology to 
localize similar local regions on protein surfaces ie, binding 
sites.18 Each chemical property, or interaction, of an amino 
acid residue is represented by a speciﬁ  c surface chemical 
feature (SCF). These are gathered in triangles to constitute 
a SuMo graph vertex. Since each SCF is associated with 
heterogeneous geometrical properties, and that triplets 
have speciﬁ  c superimposition rules (distance, angle), the 
comparison heuristic is extremely rapid. The comparison 
of a 3D pattern against all the binding sites of the PDB can 
be performed in a few minutes.19 MED-SuMo is the latest 
evolution of SuMo software developed by MEDIT-SA (see 
http://www.medit.pharma.com/). Recent developments 
have improved its binding site database, and have included 
novel functional annotation tools as presented in a recent 
study.20
Proteins are also classiﬁ  ed according to their folds,21 
eg, SCOP (Structural Classiﬁ  cation of Proteins),22,23 that 
provides a manually reﬁ  ned classiﬁ  cation with detailed and 
comprehensive descriptions of the structural and evolutionary 
relationships of the known protein structure.22,23 However, 
a critical limitation of these fold-based classiﬁ  cations is the 
use of complete protein folds or protein domains. Similarity 
of fold does not necessarily correspond to a similarity of 
function. In this paper, we focus on an interesting SCOP 
superfamily which includes the heat shock protein 90 SCOP 
family (HSP90, see Figure 1).
HSP90 is one of the most abundant proteins. Its different 
forms exhibit mainly chaperone functions associated to protein 
folding, cell survival,24 apoptosis and tumor repression.25 
It binds ATP (see Figures 2a and 2b) and is the target of 
some innovative drugs including geldanamycin which has 
enabled 50% reduction of tumor growth,26 and celasterol 
which disrupts interactions between HSP90 and Cdc37 in 
pancreatic cancer cells.27 Some recent research focussed on a 
new potential drug, radicicol. This molecule has a very high 
afﬁ  nity for HSP90 (20 nM).28 Figure 3 shows the association 
of the drug with the HSP90 at the binding site normally ﬁ  lled 
with a natural ligand.28 However, radicicol is not speciﬁ  c 
to HSP90 as it binds bacterial Sensor Kinase PhoQ,29 and 
topoisomerase VI.30 An interesting detail is that HSP90 
chaperone, MutL/DNA topoisomerase or histidine kinases 
share (see Figure 1) a common fold and that a common region 
of ATP-binding has been detected (see Figures 2c and 2d).
To analyze the similar and different features of this fold, 
we use a novel classiﬁ  cation method, MED-SuMo Multi 
approach (MED-SMA), based on the MED-SuMo technology. 
In this work, binding sites from the SCOP superfamily 
ATPase domain of HSP90 chaperone/DNA topoisomerase 
II/histidine kinase proteins are gathered in a dataset, compared 
Figure 1 Heat shock protein 90 (HSP90) SCOP superfamily: GHKL: HSP90, MutL 
proteins, pyruvate dehydrogenase kinase and DNA topoisomerase VI all share this fold.Drug Design, Development and Therapy 2009:3 61
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pairwise and classiﬁ  ed using the Markov Cluster Algorithm 
(MCL).31 Results from this method highlight common and 
distinct functional features between the analyzed proteins.
Materials and methods
Protein structure database
SCOP web site provides the list of proteins associated to a 
selected fold.23 The “ATPase domain of HSP90 chaperone/
DNA topoisomerase II/histidine kinase” superfamily contains 
116 PDB structures (see http://scop.berkeley.edu/data/scop.
b.e.ccg.A.html). The protein binding sites were selected to 
perform the classiﬁ  cation.
MED-SuMo algorithm
MED-SuMo is designed to localize similar regions associated 
to a deﬁ  ned function.18–20 A key advantage is its ability to 
detect binding site similarities even when local ﬂ  exibility 
is observed. Its heuristic is based on a 3D representation 
of macromolecules using precise SCFs. For MED-SuMo, 
a protein structure is represented by a set of functional 
groups including, for example, unbound hydrogen bond 
(Hbond) donors or acceptors, accessible sides of aromatic 
rings and carboxylate, charges, hydroxyl groups. Each 
feature encodes its chemical characteristics with precise 
geometrical properties. The overall MED-SuMo comparison 
methodology is presented in Figure 4. SCFs are displayed 
on the protein structure through a lexicographic analysis of 
the atoms in the PDB ﬁ  les, ie, a residue is represented by a 
set of representative SCFs (cf. Figures 4a, 4b). Their posi-
tions and orientations are ﬁ  ltered as shown in Figure 4c. 
Remaining SCFs are assembled into triplets with speciﬁ  c 
geometric characteristics, eg, edge size, perimeter, angles 
(cf. Figure 4d). The full triplet network is stored in the MED-
SuMo database as a graph data structure where triplets are 
the vertices and edges connect adjacent triangles (ie, those 
sharing at least two SCFs).
To compare graphs, MED-SuMo looks for compatible 
triplets; composed of compatible SCFs (cf. Figure 4e). 
These triplets are called comparison “seeds”. When a seed 
is detected, MED-SuMo extends the comparisons to the 
vertices of the neighbourhood, until no more similarities are 
found. This process enables the formation of similar patches 
(common groups of SCFs) between two graphs, weighted up 
by the MED-SuMo score.18 These comparisons are usually 
performed between a query and a database of precompiled 
graphs. Two kinds of MED-SuMo database are commonly 
used: the binding site database that is composed from the 
SCFs around co-crystallized ligands and the full surface 
database, composed from SCFs covering the whole surface of 
each studied protein, typically the entire PDB. The database 
characteristics are deﬁ  ned by three essential parameters: 
the size of the ligand environment taken into account 
a) b)
d) c)
Figure 2 An example of heat shock protein 90 (HSP90) bound to its natural ligand. 
The protein shown is an HSP90 of Saccharomyces cerevisiae (PDB code 1AMW). a–b) 
underlines the close contacts (in red) of the ADP (in blue). c–d) underlines in green 
the common binding region of this SCOP superfamily.
Figure 3 An example of heat shock protein 90 (HSP90) bound to radicicol. Both views represent an HSP90 of Saccharomyces cerevisiae (PDB code 1BGQ) bound to the drug 
radicicol shown in blue (see Figure 2 to compare with the natural ligand of HSP90).Drug Design, Development and Therapy 2009:3 62
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by MED-SuMo (named ligand_radius and only concerning 
the binding site database), the maximal distance between two 
SCFs to be included in a triplet (named edge_max) and the 
maximal perimeter for a triangle (named max_edge_sum).
Classiﬁ  cation of protein binding sites
As noted, MED-SuMo has an interesting and original 
approach to detect structural and functional similarities 
between protein binding sites.18–20 We decided to apply this 
approach to classify deﬁ  ned sets of structures. This new 
method, named MED-SuMo Multi Approach (MED-SMA), 
enables the comparison of all binding sites from a set of pro-
teins using a pairwise comparison system. Matching regions 
are found in the binding sites to derive a similarity graph. 
This graph is classiﬁ  ed with the MCL31. Figure 5 illustrates 
the overall procedure. For this work, MED-SMA is only 
applied on the MED-SuMo binding sites database.
To begin, a set of proteins is selected (see previous 
paragraph, cf. Figure 5a). Ligands’ characteristics are used 
to decide which binding sites to include in the MED-SuMo 
database. Once the ligands parameters are set, the database 
is created and the pairwise comparison is launched using the 
standard MED-SuMo comparison procedure.
These comparisons highlight similar regions between 
pairs of binding sites (cf. Figure 5b) represented by groups of 
SCFs called patches. Only comparisons with a MED-SuMo 
score higher than a ﬁ  xed cut-off (parameter score_min) are 
accepted. Patches associated to the same binding sites are 
analyzed: if two patches share enough SCFs (deﬁ  ned by a 
threshold parameter named covering_factor), they are merged 
in a multipatch (cf. Figure 5c). A multipatch is a set of SCFs 
common to several binding sites of the protein set; they can 
also be called sub-sites. They represent the true meaningful 
common regions of binding sites. They have two properties: 
(i) enough SCFs are in common, such that binding sites are 
structurally and chemically similar, and (ii) they can provide 
a measure of sub-pocket similarity. These measures are used 
to compute a similarity matrix. For this matrix, the MED-
SuMo score between matching multipatches is calculated 
(cf. Figure 5d). MCL is used to interpret the matrix through 
Binding site Connection SCFs localization
MEDSuMo database
Low compatibility score
Good compatibility score
Research
e)
d)
c) b) a)
Figure 4 MED-SuMo comparison procedure. a) Localization of an interesting part of the protein surface often characterized by the presence of a co-crystallized ligand. 
b) Surface chemical features (SCFs) are displayed on the protein structure through a lexicographic analysis of the PDB ﬁ  les. c) SCFs are gathered in triplets. d) The triplet 
network is then stored as a graph data structure with the triplets as vertices and with edge connecting adjacent triplets. e) The query graph (in blue) is compared to the 
database graphs (in green and brown); they usually represent all binding sites of the PDB. Compatible triplets are detected, ie, they are formed by compatible SCFs.   At last, the 
corresponding graphs (hits) are ranked in regard to their compatibility score.Drug Design, Development and Therapy 2009:3 63
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classiﬁ  cation of the protein binding site set into clusters of 
sub-sites (cf. Figure 5e). A 2D plot of the clusters can be 
visualized using tools such as Biolayout.32,33
Results
MED-SMA classiﬁ  cation
To generate the MED-SuMo database, only binding sites 
co-crystallized with ligands with more than ten atoms are 
selected. Of the originally selected 116 PDB structures, 101 
satisfy this ﬁ  lter. This yields a total of 146 binding sites in the 
ﬁ  nal database. Several kinds of ligands are present, purines, eg, 
adenosine tri-phosphate or N-ethyl-5’-carboxamido adenosine, 
or potential drugs, eg, Radicicol or Novobiocin. Of these 146 
binding sites, 78 are from HSP90, 38 from topoisomerase/
MutL, 26 are from histidine kinase, and four are from α-keto-
acid dehydrogenase kinase C (BCK). The database parameters 
are set to a ligand radius of 6.0 Å and triangle parameters of 
13 Å and 39 Å (respectively edge_max and max_edge_sum). 
To classify this dataset, MED-SMA takes around two minutes 
on a four CPU machine. The classiﬁ  cation parameters are set 
to a minimal compatibility score (score_min) of 4.0 and a 
covering_factor of 0.6.
Here, the MED-SMA approach produces ﬁ  ve clusters. 
The distribution of these clusters in regards to the SCOP 
families is shown in Table 1 and the composition of each 
cluster is available in Supplementary data 1.
Two types of MED-SMA clusters are seen. Three clusters 
are homogeneous as they contain only proteins from a unique 
SCOP family (MED-SMA clusters 1, 3, and 5). Two clusters 
are heterogeneous as they contain at least two SCOP families 
(MED-SMA clusters 2 and 4). MED-SMA clusters 1 and 3 
are speciﬁ  c to topoisomerase/MutL while cluster 5 is speciﬁ  c 
to histidine kinase. MED-SMA cluster 2 contains binding 
sites from two families (ie, BCK and histidine kinase) and 
MED-SMA cluster 4’s binding sites are from three of the four 
families (HSP90, topoisomerase/MutL, and BCK).
MED-SMA clusters 1 and 3
MED-SMA clusters 1 and 3 contain 22 and 6 binding sites 
of the 38 proteins of the topoisomerase/MutL/DNA gyrase 
a)
b) c)
d) e)
Figure 5 Global steps of binding site classiﬁ  cation heuristic. MED-SuMo Multi approach (MED-SMA) can be divided in 5 steps: a) Database construction: all selected binding 
sites are stored as graph in the MED-SuMo database. b) Pairwise comparisons: all binding sites are compared to each other to detect similarities between pairs (lines with dif-
ferent colors).   These similarities are called patches c) If overlapping patches have a certain amount of common SCFs (more than a threshold value: parameter covering_factor), 
they are merged in multipatches (grey circles). d) MED-SuMo scores between pairs of multipatches are calculated and used to create a similarity matrix which is classiﬁ  ed by 
MCL (Markov Cluster Algorithm) to create clusters of binding sites. e) Biolayout 2D view of the MED-SMA clusters.Drug Design, Development and Therapy 2009:3 64
Doppelt-Azeroual et al
family, respectively. The two forms of topoisomerases IV 
structures of Escherichia coli (PDB code 1S14 and 1S16) 
share 99.5% sequence identity except for a 23 residue insertion 
in 1S16. These two proteins are separated by MED-SMA. 
A precise look at their ATP-binding sites highlights structural 
similarities but, above all, some strong distinctions. Figure 6 
shows a 3D superimposition of these proteins. The region 
noted (1) on Figure 6 shows an excellent superimposition 
of several β-sheets and 2 α-helixes. Moreover a part of the 
binding sites is also similar, with a set of ﬁ  ve SCFs well 
superimposed (noted [2] on Figure 6). Conversely, the other 
side of the binding site (noted [3] on Figure 6) is quite diverse. 
Ligands of these two topoisomerases are novobiocin for 1S14 
and phosphoaminophosphonic acid-adenylate ester (ANP) 
for 1S16. They are not located at the same spatial position 
and their overlap is small (∼10 atoms) compared to their 
respective sizes (44 atoms for novobiocin and 31 atoms for 
ANP). Furthermore, novobiocin can not ﬁ  t at all in the 1S16 
binding site, otherwise a steric clash appears with 1S16’s 
α helixes (noted [4] on Figure 6). Thus, binding sites from 
MED-SMA clusters 1 and 3 do not share sufﬁ  cient similarities 
to be gathered by MED-SMA, neither can they bind the same 
kind of molecules. Interestingly, the two forms are very close 
but the residue insertion causes strongly diverging afﬁ  nities 
to ligands of this class.34 So, our results reinforce the study 
of Bellon and colleauges. Moreover, it characterizes with 
elegance the fact that these two distinct local conformations 
are found in different related proteins.
Table 1 Confusion matrix of the SCOP families within the clusters. The MED-SuMo clusters are arranged vertically whereas the SCOP 
families are arranged horizontally. MED-SuMo clusters #1, #3 and #5 are homogeneous clusters, they only contain protein from: SCOP 
DNA gyrase/MutL family (for #1 and #3) and histidine kinase, respectively. MED-SuMo clusters #2 and #4 are heterogeneous
SCOP fam MED-Clusters HSP90 DNA gyrase MutL Histidine kinase A-ketoacid dehydrogenase kinase C
10 2 2 0 0
20 0 1 5 3
30 6 0 0
47 8 1 0 0 1
50 0 1 1 0
(3)
(4)
(2)
(1)
(1)
(1)
Figure 6 Superimposition of two topoisomerase VI separated by MED-SMA. PDB codes 1S16 (red) and 1S14 (green) are superimposed.   They are both topoisomerase but 
their binding sites do not share enough similarity to be grouped in the same cluster.    This ﬁ  gure is divided by several numbered regions: 1) Protein structure similarities. two α 
helixes and several β-sheets are common to both structures. 2) Low similarity in binding sites underlined by ﬁ  ve SCFs. 3) Difference between the two structures on the other 
side of the binding site. 4) Potential clash between the query ligand and the hit protein structure.Drug Design, Development and Therapy 2009:3 65
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MED-SMA cluster 4
As mentioned earlier, MED-SMA cluster 4 gathers three 
different SCOP families. It is the largest cluster, containing 
89 binding sites. All HSP90s of the dataset are present 
(78 binding sites), 10 from mutL/DNA topoisomerase family 
(with one topoisomerase VI, ﬁ  ve MutL, and four PMS2) and 
one from BCK family. Only the histidine kinase family is 
not represented in this MED-SMA cluster. The ligands are 
highly diverse with 48 unique ligands found.
Binding sites in this MED-SMA cluster share a common 
set of SCFs. Figure 7 shows a global superimposition of one 
structure of each family. The white rectangles show similari-
ties whereas the remainder is very different as represented 
in the global superimposition of all the protein families in 
Figure 1. Figure 8 shows a close view around the radicicol. 
The eight labelled SCFs (circled in yellow) are shared by 
all superimposed structures in Figure 7. They are located all 
around the ligand meaning that the similarities concern the 
whole binding site.
The fact that MED-SMA gathers the binding sites from 
three different SCOP families implies a high probability that 
the binding modes are related. Considering the nonspeciﬁ  c 
drug radicicol which binds HSP90 and topoisomerase VI,30 we 
could easily make the hypothesis that this drug would also bind 
the different proteins included in this MED-SMA cluster.
MED-SMA clusters 2 and 5
MED-SMA clusters 2 and 5 mostly consist of histidine kinase. 
MED-SMA cluster 2 is heterogeneous while MED-SMA 
cluster 5 is homogeneous. Cluster 5 is very worthwhile 
because it is pure and that the dimensions of its binding sites 
are very similar as they all bind purine ligands. Since the 
binding sites gathered by MED-SMA share binding modes 
to ligands, this type of cluster could be used to search 
for speciﬁ  c drugs; here, drugs to inhibit histidine kinase 
CheA action.
Interestingly, MED-SMA cluster 2 also contains two 
histidine kinase CheA (PDB codes 2CH4 and 1I5D). The 
separation of proteins from the same family in two different 
clusters is due to differences between their binding sites. 
When 1I5D’s binding site is compared to histidine kinase 
CheA from cluster 5, the MED-SuMo score is less than 4.0 
(which is the cut-off we chose for the pairwise comparison 
step). So, a drug designed to inhibit binding sites of 
cluster 5 would not bind (or not with the same afﬁ  nity) the 
two excluded histidine kinase CheA binding sites.
Figure 7 Superimposition of four proteins from three distinct SCOP families but gathered in the same cluster by MED-SMA. (PDB codes 2HKJ [green], 2CCT [cyan], 1B63 
[pink] 1JM6 [yellow]).   The white rectangles show similarities around the ligands and also the helices from the Bergerat fold.   The rest of the superimposition is quite messy, 
as protein global folds are very different.Drug Design, Development and Therapy 2009:3 66
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Another interesting point on MED-SMA cluster 2 is that it 
contains both BCK and anti-sigma factor spoIIab. These two 
proteins are inhibited like HSP90 by the radicicol. However, 
as they are not associated to MED-SMA cluster 4, it may 
reﬂ  ect a speciﬁ  c binding mode.
Discussion
The detection of functional sites on protein surfaces is 
important for the identiﬁ  cation of biological activity. Ligand-
protein interactions occur for the majority of protein struc-
tures and they are implicated in major biological processes. 
However, with no help from known related sequences or 
structures their detection is difﬁ  cult.14 Several innovative 
approaches have been proposed, ie, the use of hydrophobicity 
distribution on protein structures based on the fuzzy oil drop 
model,35 the destabilization of limited protein regions,36 
phylogenomic classiﬁ  cation of protein sequences37 or the 
classiﬁ  cation of known protein catalytic sites.38 Prediction 
of protein functional sites is an important step to identify 
small-molecule interactions for drug discovery39 and it can 
be very useful to optimize drug design.40 Another valuable 
application is as a pre-processing step to reduce the search 
space for rigorous computational docking algorithms.
Methods to compare binding sites have been developed 
using various kinds of structural descriptors, eg, CavBase 
uses pseudocenters,41 and the strong hypothesis that chemical 
similarity and activity are linked. In this ﬁ  eld, MED-SuMo 
has an interesting approach using SCFs. Each SCF repre-
sents a pertinent chemical property and is described with 
speciﬁ  c geometric rules. The search for equivalent binding 
sites is performed by detection of similar graphs.42 The 
speciﬁ  c geometric rules of each SCF enable the heuristic to 
be quite fast. So, MED-SuMo provides an interesting and 
original method to detect structural and functional similarities 
between protein binding sites. Unlike MED-SuMo, very few 
methods enable functional classiﬁ  cation of sets of binding 
sites43 and speciﬁ  c binding sites are usually chosen (protein 
kinase) for the published work. Comparing our protocol with 
others is quite difﬁ  cult.
Here, it is applied in a new clustering approach where 
the ligand environment is classiﬁ  ed. An application to a 
particular protein fold, the Bergerat ATP-binding fold char-
acterized as the ATPase domain of HSP90 chaperone/DNA 
topoisomerase II/histidine kinase SCOP superfamily is 
described here. The constituent families are quite different 
but their ATP binding sites appear quite alike. MED-SMA 
detects ﬁ  ve different clusters. Three out of ﬁ  ve are speciﬁ  c 
to a single family. These three MED-SMA clusters highlight 
the speciﬁ  city of the binding sites; for example; no molecule 
binding to cluster 1’s binding site would also bind MED-SMA 
Figure 8 A close view around the radicicol ligand.   The eight labelled SCFs (circled in yellow) are shared by all superimposed structures in Figure 7.   They are located all around 
the ligand, which means that the similarities concern the whole binding site.Drug Design, Development and Therapy 2009:3 67
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cluster 2 sites with the same interactions. The fact that the 
ligands are similar in MED-SMA cluster 1 and 2 (eg, ADP) 
emphasizes the previous observation. The ligands are the 
same whereas the binding modes are different. Oppositely, 
MED-SMA cluster 4 gathers three different families. The 3D 
superimposition from MED-SuMo, points out the difference 
of the global fold whereas the Bergerat fold can be observed 
(white rectangle on Figure 7). Interestingly, SCFs can be 
found all around the query ligand (cf. Figure 7), meaning 
that there is a global similarity of the binding sites from the 
three SCOP families. Moreover, this result is consistent with 
the experimental data as the proteins from these three SCOP 
families all bind radicicol.28–30,44
These different results demonstrate the ability of the 
method to gather binding sites with related binding modes. 
This kind of relationship between families is very interesting 
and their identiﬁ  cation is a direct application for MED-SMA. 
Moreover, with this kind of association, we can validate the 
assertion that functions can be assigned to unknown proteins 
by associating them to a speciﬁ  c best matching cluster. 
Matching clusters rather than single structures overcomes 
most of the noise in both the assignments and in the functions 
of those assigned matches. Other applications are planned, 
for example, a more general kinase classiﬁ  cation using MED-
SMA is under investigation.
Conclusions
This example clearly shows that our approach is well suited 
for ﬁ  nding common and distinct characteristics of ligand 
binding pockets. Thus, close proteins can have different local 
binding modes, while more distant ones can share common 
binding features ie, a potential cross-reaction may be pos-
sible. For instance, proteins associated to radicicol are found 
in the same MED-SMA clusters. This approach is clearly 
applicable to structural genomics research. As noted by 
Ferrè and colleagues, functional patches associated to a large 
collection of protein surface cavities can be used to provide 
functional clues for protein with unknown structures.45 This 
observation is shared from our study. Thus, MED-SuMo is an 
approach that may improve the efﬁ  ciency and effectiveness 
of early steps along the drug discovery path, improving early 
lead choices, enhancing poor leads, or aiding multivariate 
optimizations. This study further demonstrates that MED-
SuMo is appropriate for both annotating protein structures 
and for deriving structural functional classiﬁ  cations.
Finally, with its effectiveness at dealing with the entire 
PDB, and the parallelisation of the computational process in 
course, MED-SuMo is well-suited to large-scale applications. 
In fact it is currently used to resolve the big challenge of the 
POPS project (see http://www.pops-systematic.org/) in clas-
sifying every binding site represented in the PDB.
Software licensing
Commercial information regarding MED-SuMo is available 
at http://www.medit.fr/. Questions about MED-SuMo licens-
ing should be addressed to info@medit.fr. Researcher from 
the Inserm Institute UMR-S 726 has no ﬁ  nancial interests 
in MEDIT and collaborates with this company only for the 
present project. Therefore, MEDIT SA has the exclusivity 
for MED-SuMo sales.
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Supplementary data
Supplementary table 1
MED-SMA cluster ID PDB_LIG_ID Ligand name SCOP family
CL_1 1EI1_1_92 ANP DNA_Gyrase_B_EColi
CL_1 1EI1_2_90 ANP DNA_Gyrase_B_EColi
CL_1 1MX0_1_31 ANP TOPO_VI
CL_1 1MX0_2_29 ANP TOPO_VI
CL_1 1MX0_3_28 ANP TOPO_VI
CL_1 1MX0_4_25 ANP TOPO_VI
CL_1 1MX0_5_22 ANP TOPO_VI
CL_1 1MX0_6_21 ANP TOPO_VI
CL_1 1PVG_1_1 ANP DNA_TOPO_II_Byeast
CL_1 1PVG_2_0 ANP DNA_TOPO_II_Byeast
CL_1 1QZR_1_117 CDX DNA_TOPO_II_Byeast
CL_1 1QZR_2_113 ANP DNA_TOPO_II_Byeast
CL_1 1QZR_3_111 ANP DNA_TOPO_II_Byeast
CL_1 1S16_1_102 ANP TOPO_IV
CL_1 1S16_2_100 ANP TOPO_IV
CL_1 1Z59_1_17 ADP TOPO_VI
CL_1 1Z5A_1_11 ADP TOPO_VI
CL_1 1Z5A_2_8 ADP TOPO_VI
CL_1 1Z5B_1_86 ADP TOPO_VI
CL_1 1Z5B_2_84 ADP TOPO_VI
CL_1 1Z5C_1_9 ADP TOPO_VI
CL_1 1Z5C_2_5 ADP TOPO_VI
CL_2 1GJV_1_112 SAP alpha-ketoacid_dehydrogenase_kinase
CL_2 1GKZ_1_33 ADP alpha-ketoacid_dehydrogenase_kinase
CL_2 1I5D_1_118 128 Histidine_Kinase_CheA
CL_2 1ID0_1_10 ANP Histidine_Kinase_PhoQ
CL_2 1JM6_2_61 ADP Pyruvate_dehydrogenase_kinase
CL_2 1L0O_1_75 ADP Anti-sigma_factor_spoIIab
CL_2 1L0O_2_73 ADP Anti-sigma_factor_spoIIab
CL_2 1TH8_1_123 ADP Anti-sigma_factor_spoIIab
CL_2 1TH8_1_124 ADP Anti-sigma_factor_spoIIab
CL_2 1THN_1_104 ADP Anti-sigma_factor_spoIIab
CL_2 1THN_2_101 ADP Anti-sigma_factor_spoIIab
CL_2 1TID_1_35 ATP Anti-sigma_factor_spoIIab
CL_2 1TID_2_32 ATP Anti-sigma_factor_spoIIab
CL_2 1TIL_1_27 ATP Anti-sigma_factor_spoIIab
CL_2 1TIL_2_24 ATP Anti-sigma_factor_spoIIab
CL_2 1TIL_3_23 ATP Anti-sigma_factor_spoIIab
CL_2 2C2A_1_120 ADP Sensor_histidine_kinase_TM0853
CL_2 2CH4_1_56 ANP Histidine_Kinase_CheA
CL_3 1AJ6_1_76 NOV DNA_GYRASE_B_EColi
CL_3 1KIJ_1_66 NOV DNA_GYRASE_B_TT
CL_3 1KIJ_2_64 NOV DNA_GYRASE_B_TT
CL_3 1KZN_1_52 CBN DNA_GYRASE_B_EColi
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Supplementary table 1 (Continued)
MED-SMA cluster ID PDB_LIG_ID Ligand name SCOP family
CL_3 1S14_1_105 NOV TOPO_IV
CL_3 1S14_2_103 NOV TOPO_IV
CL_4 1A4H_1_62 GMY HSP90_Yeast
CL_4 1AM1_1_37 ADP HSP90_Yeast
CL_4 1AMW_1_7 ADP HSP90_Yeast
CL_4 1B62_1_16 ADP MulL
CL_4 1B63_1_91 ANP MulL
CL_4 1BGQ_1_55 RDC HSP90_Yeast
CL_4 1BYQ_1_99 ADP HSP90_Human
CL_4 1EA6_1_110 ADP PMS2
CL_4 1EA6_2_109 ADP PMS2
CL_4 1H7U_1_46 ATG PMS2
CL_4 1H7U_2_44 ATG PMS2
CL_4 1JM6_1_63 ADP Pyruvate_dehydrogenase_kinase
CL_4 1NHH_1_43 ANP MulL
CL_4 1NHI_1_108 ANP MulL
CL_4 1NHJ_1_42 ANP MulL
CL_4 1OSF_1_83 KOS HSP90_Human
CL_4 1QY5_1_13 NEC HSP90_Dog
CL_4 1QY8_1_87 RDI HSP90_Dog
CL_4 1QYE_1_143 CDY HSP90_Dog
CL_4 1TBW_1_107 AMP HSP90_Dog
CL_4 1TBW_2_106 AMP HSP90_Dog
CL_4 1TC0_1_125 ATP HSP90_Dog
CL_4 1TC0_2_121 ATP HSP90_Dog
CL_4 1TC6_1_116 ADP HSP90_Dog
CL_4 1TC6_2_114 ADP HSP90_Dog
CL_4 1U0Y_1_26 PA7 HSP90_Dog
CL_4 1U0Z_1_95 RDC HSP90_Dog
CL_4 1U0Z_6_93 RDC HSP90_Dog
CL_4 1U2O_1_3 NEC HSP90_Dog
CL_4 1U2O_2_2 NEC HSP90_Dog
CL_4 1UY6_1_88 PU3 HSP90_Human
CL_4 1UY7_1_6 PU4 HSP90_Human
CL_4 1UY8_1_82 PU5 HSP90_Human
CL_4 1UY9_1_4 PU6 HSP90_Human
CL_4 1UYC_1_144 PU7 HSP90_Human
CL_4 1UYD_1_74 PU8 HSP90_Human
CL_4 1UYE_1_141 PU9 HSP90_Human
CL_4 1UYF_1_71 PU1 HSP90_Human
CL_4 1UYG_1_138 PU2 HSP90_Human
CL_4 1UYH_1_68 PU0 HSP90_Human
CL_4 1UYI_1_135 PUZ HSP90_Human
CL_4 1UYK_1_133 PUX HSP90_Human
CL_4 1UYM_1_132 PU3 HSP90_Human
CL_4 1YC1_1_15 4BC HSP90_Human
CL_4 1YC3_1_14 4BC HSP90_Human
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MED-SMA cluster ID PDB_LIG_ID Ligand name SCOP family
CL_4 1YC4_1_89 43P HSP90_Human
CL_4 1YET_1_39 GDM HSP90_Human
CL_4 1YSZ_1_131 NEC HSP90_Dog
CL_4 1YT0_1_80 ADP HSP90_Dog
CL_4 1ZW9_1_137 H64 HSP90_Yeast
CL_4 1ZWH_1_58 RDE HSP90_Yeast
CL_4 2BRC_1_20 CT5 HSP90_Yeast
CL_4 2BRE_1_19 KJ2 HSP90_Yeast
CL_4 2BRE_2_18 KJ2 HSP90_Yeast
CL_4 2BSM_1_77 BSM HSP90_Human
CL_4 2BT0_1_81 CT5 HSP90_Human
CL_4 2BT0_2_79 CT5 HSP90_Human
CL_4 2BYH_1_69 2D7 HSP90_Human
CL_4 2BYI_1_134 2DD HSP90_Human
CL_4 2BZ5_1_70 AB4 HSP90_Human
CL_4 2BZ5_2_65 AB4 HSP90_Human
CL_4 2CCS_1_98 4BH HSP90_Human
CL_4 2CCT_1_30 2E1 HSP90_HumanC
CL_4 2CCU_1_97 2D9 HSP90_Human
CL_4 2CDD_1_96 CT5 HSP90_Human
CL_4 2CDD_2_94 CT5 HSP90_Human
CL_4 2EXL_1_41 GMY HSP90_Dog
CL_4 2EXL_2_40 GMY HSP90_Dog
CL_4 2FWY_1_12 H64 HSP90_Human
CL_4 2FWZ_1_85 H71 HSP90_Human
CL_4 2FXS_1_78 RDA HSP90_Yeast
CL_4 2FYP_1_60 RDE HSP90_Dog
CL_4 2FYP_2_59 RDE HSP90_Dog
CL_4 2GFD_1_72 RDA HSP90_Dog
CL_4 2GFD_2_67 RDA HSP90_Dog
CL_4 2GQP_1_130 PA7 HSP90_Dog
CL_4 2GQP_2_128 PA7 HSP90_Dog
CL_4 2H55_1_122 DZ8 HSP90_Human
CL_4 2H8M_1_139 NEI HSP90_Dog
CL_4 2H8M_2_136 NEI HSP90_Dog
CL_4 2HCH_1_142 N5A HSP90_Dog
CL_4 2HCH_2_140 N5A HSP90_Dog
CL_4 2HG1_1_36 N5O HSP90_Dog
CL_4 2HG1_2_34 N5O HSP90_Dog
CL_4 2HKJ_1_38 RDC TOPOVI
CL_4 2IWS_1_48 NP4 HSP90_Yeast
CL_4 2IWU_1_45 NP5 HSP90_Yeast
CL_4 2IWX_1_00 M1S HSP90_Yeast
CL_4 2UWD_1_126 2GG HSP90_Human
CL_5 1I58_1_129 ACP Histidine_Kinase_CheA
CL_5 1I58_2_127 ADP Histidine_Kinase_CheA
CL_5 1I59_1_57 ANP Histidine_Kinase_CheA
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MED-SMA cluster ID PDB_LIG_ID Ligand name SCOP family
CL_5 1I59_2_54 ADP Histidine_Kinase_CheA
CL_5 1I5A_1_51 ACP Histidine_Kinase_CheA
CL_5 1I5A_2_49 ACP Histidine_Kinase_CheA
CL_5 1I5B_1_119 ANP Histidine_Kinase_CheA
CL_5 1I5B_2_115 ANP Histidine_Kinase_CheA
CL_5 1I5C_1_50 ADP Histidine_Kinase_CheA
CL_5 1I5C_2_47 ADP Histidine_Kinase_CheA
CL_5 2CH4_2_53 ANP Histidine_Kinase_CheA